Contribute Try STAT+ Today

Celsius Therapeutics, a startup built around sequencing genetic material in thousands of an individual’s cells, announced a new deal with Janssen, Johnson and Johnson’s biotech subsidiary, on Tuesday — a partnership that will be the largest proving ground yet for single-cell RNA sequencing technology.

The partnership — for which financial terms were not disclosed — will give Celsius the chance to test its technology with a far bigger dataset than any company has ever used before. The sheer scale could put a renewed spotlight on single-cell RNA sequencing, which scientists hope could bring about more detailed and precise pictures of how individual genes in individual cells misbehave in a particular condition.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy